Kala Bio Inc 's (KALA) Outlook - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 
Kala Bio inc   (NASDAQ: KALA)
 



  Kala Bio inc Outlook

On March 29 2024 the Kala Bio inc provided following guidance

KALA BIO, Inc. announced its financial results for the fourth quarter and full year 2023, as well as provided a corporate update. The company is currently advancing its ongoing Phase 2b CHASE trial of KPI-012 for Posterior Corneal Epithelial Dystrophy (PCED), with topline data expected by the end of 2024. Additionally, KALA BIO is exploring opportunities to expand the use of KPI-012 into additional corneal indications.

As of December 31, 2023, the company's cash resources, combined with proceeds from a private placement in March 2024 and anticipated funding from a California Institute for Regenerative Medicine (CIRM) award, are projected to support operations until the third quarter of 2025.

KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for rare and severe eye diseases. The company's dedication to research and development aims to address unmet medical needs in the field of ophthalmology. With ongoing clinical trials and strategic expansion plans, KALA BIO continues to work towards providing effective treatments for patients in need.





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.